Femasys Inc. to Participate in Upcoming January Investor Conferences

Rhea-AI Summary

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, announced its participation in two upcoming virtual conferences. The LifeSci Partners 11th Annual Corporate Access Event will feature CEO Kathy Lee-Sepsick on January 6, 2022, discussing gender equality in life sciences. Additionally, Femasys will present at the H.C. Wainwright BioConnect Conference, with a recording available from January 10, 2022. Femasys develops minimally invasive technologies, including FemBloc® and FemaSeed® for reproductive health needs.

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11^th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

Participation and presentation details are below:

• LifeSci Partners Corporate Access Event:
  • Kathy Lee-Sepsick, President, Chief Executive Officer and Founder, will present on a panel entitled, "The Role of Gender Equality in Changing the Landscape of Life Sciences Innovation & Investment” on Thursday, January 6^th, 12:00 pm ET.
    
    
  • The Femasys management team will be available for 1x1 meetings with interested investors during January 6^th -7^th. Register here to submit a meeting request or to hear the panel discussion.

• H.C. Wainwright BioConnect Conference:
  • Femasys will present at the H.C. Wainwright BioConnect Conference and a recording of the presentation will be accessible beginning January 10^th at 7:00 am ET. To listen to the event, please click here to register and access the webcast
    

About Femasys

Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc^® permanent birth control and FemaSeed^® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue^®, is currently marketed in the United States. Femasys is also advancing FemCerv^®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com

Femasys Inc.
Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com

FAQ

When is the LifeSci Partners Corporate Access Event for Femasys?

The LifeSci Partners Corporate Access Event will take place virtually from January 5 to January 7, 2022.

What will Femasys present during the BioConnect Conference?

Femasys will present at the H.C. Wainwright BioConnect Conference, with a recording available from January 10, 2022, at 7:00 am ET.

Who is presenting for Femasys at the LifeSci Partners event?

Kathy Lee-Sepsick, the President and CEO of Femasys, will present on January 6, 2022.

What technologies does Femasys develop for women's health?

Femasys develops minimally invasive technologies including FemBloc® for permanent birth control and FemaSeed® for localized directional insemination.

How can investors meet Femasys management during the events?

Investors can request 1x1 meetings with Femasys management on January 6 and 7, 2022, during the LifeSci Partners event.